Tanvex BioPharma, Inc. (6541.TW)
TWD 58.5
(-3.62%)
TWD 58.5
(-3.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.75 Billion TWD | -36.1% |
| 2022 | -1.3 Billion TWD | -4.1% |
| 2021 | -1.25 Billion TWD | 32.8% |
| 2020 | -1.86 Billion TWD | 8.69% |
| 2019 | -2.04 Billion TWD | -12.99% |
| 2018 | -1.75 Billion TWD | -42.3% |
| 2017 | -1.27 Billion TWD | -2.96% |
| 2016 | -1.12 Billion TWD | -60.7% |
| 2015 | -767.84 Million TWD | -80.23% |
| 2014 | -426.03 Million TWD | -54.53% |
| 2013 | -275.69 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -290.9 Million TWD | 15.42% |
| 2024 Q1 | -349.62 Million TWD | 20.62% |
| 2023 Q4 | -408.73 Million TWD | 0.22% |
| 2023 Q2 | -409.72 Million TWD | 20.85% |
| 2023 FY | - TWD | -36.1% |
| 2023 Q3 | -409.64 Million TWD | 0.02% |
| 2023 Q1 | -517.63 Million TWD | -31.54% |
| 2022 Q2 | -345.37 Million TWD | -36.65% |
| 2022 Q4 | -393.52 Million TWD | -25.65% |
| 2022 Q3 | -313.19 Million TWD | 9.32% |
| 2022 Q1 | -252.73 Million TWD | 6.92% |
| 2022 FY | - TWD | -4.1% |
| 2021 Q4 | -271.53 Million TWD | 17.15% |
| 2021 FY | - TWD | 32.8% |
| 2021 Q2 | -310.13 Million TWD | 9.81% |
| 2021 Q1 | -343.85 Million TWD | 14.18% |
| 2021 Q3 | -327.73 Million TWD | -5.68% |
| 2020 Q4 | -400.65 Million TWD | -0.27% |
| 2020 Q1 | -559.96 Million TWD | -17.0% |
| 2020 Q2 | -505.05 Million TWD | 9.81% |
| 2020 Q3 | -399.56 Million TWD | 20.89% |
| 2020 FY | - TWD | 8.69% |
| 2019 Q4 | -478.6 Million TWD | 24.01% |
| 2019 Q1 | -458.72 Million TWD | -5.0% |
| 2019 FY | - TWD | -12.99% |
| 2019 Q2 | -475.55 Million TWD | -3.67% |
| 2019 Q3 | -629.78 Million TWD | -32.43% |
| 2018 Q3 | -448.66 Million TWD | 27.49% |
| 2018 FY | - TWD | -42.3% |
| 2018 Q2 | -618.78 Million TWD | -103.91% |
| 2018 Q1 | -303.45 Million TWD | 13.47% |
| 2018 Q4 | -436.89 Million TWD | 2.62% |
| 2017 Q1 | -322.92 Million TWD | 26.98% |
| 2017 Q2 | -320.71 Million TWD | 0.68% |
| 2017 FY | - TWD | -2.96% |
| 2017 Q3 | -276.1 Million TWD | 13.91% |
| 2017 Q4 | -350.71 Million TWD | -27.02% |
| 2016 FY | - TWD | -60.7% |
| 2016 Q2 | -274.68 Million TWD | -17.26% |
| 2016 Q3 | -282.74 Million TWD | -2.94% |
| 2016 Q4 | -442.25 Million TWD | -56.41% |
| 2016 Q1 | -234.25 Million TWD | -4.03% |
| 2015 Q2 | -156.79 Million TWD | 0.0% |
| 2015 Q4 | -225.17 Million TWD | 2.3% |
| 2015 Q3 | -230.48 Million TWD | -46.99% |
| 2015 Q1 | -156.79 Million TWD | -27.96% |
| 2015 FY | - TWD | -80.23% |
| 2014 Q4 | -122.53 Million TWD | 0.0% |
| 2014 Q2 | -91.17 Million TWD | 0.0% |
| 2014 Q1 | -91.17 Million TWD | 0.0% |
| 2014 FY | - TWD | -54.53% |
| 2014 Q3 | -122.53 Million TWD | -34.4% |
| 2013 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Biotechnology Corp. | 221.06 Million TWD | 893.656% |
| Sinphar Pharmaceutical Co.,Ltd. | 582.94 Million TWD | 400.965% |
| Panion & Bf Biotech Inc. | 327.21 Million TWD | 636.172% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 473.81 Million TWD | 470.284% |
| GenMont Biotech Incorporation | 71.76 Million TWD | 2544.622% |
| Abnova (Taiwan) Corporation | 81.2 Million TWD | 2260.421% |
| Adimmune Corporation | -512.42 Million TWD | -242.381% |
| Polaris Group | -1.38 Billion TWD | -26.265% |
| Energenesis Biomedical CO.,LTD. | -244.57 Million TWD | -617.343% |
| UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | -3017.592% |
| PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | -396.763% |